December 6, 2021

What can clinicians do to continue treating patients with Hodgkin’s lymphoma (HL) during a widespread shortage of the drugs typically used to do so? This study, published in Blood, reviewed this predicament experienced by hematologists/oncologists in Mexico from mid-2019 to mid-2021. The study will be presented at the 2021 ASH Annual Meeting & Exposition.  During the drug...

Classic Hodgkin lymphoma can usually be treated successfully in younger patients using ABVD (Adriamycin, bleomycin, vinblastine, and dacarbazine). However, older patients with the disease have a relatively poor prognosis, and ABVD’s efficacy and tolerability in this population are uncertain. This retrospective study, published in Internal Medicine, analyzed the outcomes of older patients with classic Hodgkin lymphoma treated...

Although Hodgkin lymphoma is treatable, past population-based studies have reported worse survival outcomes for non-white children, adolescents, and young adults. This study, published in Cancer, analyzed the survival rates of this patient population with Hodgkin lymphoma while adjusting for sociodemographic factors and treatment.  This study relied on data from 4,807 patients with Hodgkin lymphoma younger than...

This study, published in JNCI: Journal of the National Cancer Institute, examined the impact of treatment-related morbidity on long-term, cause-specific mortality in patients with Hodgkin lymphoma. The study included 4,919 patients with Hodgkin lymphoma who were treated before age 51 between 1965 and 2000. The median follow-up was 20.2 years. The researchers used the data gathered...

Although rare, there are cases in which classic Hodgkin lymphoma (CHL) and follicular lymphoma (FL) occur simultaneously at the same site. Known as composite classic Hodgkin lymphoma and follicular lymphoma (CHLFL), this condition is rare and not well understood. This article, published in the American Journal of Clinical Pathology, examined two case studies that showed...

A retrospective analysis of patients with classic Hodgkin lymphoma (cHL) treated with PD-1 inhibitors will be presented at the 2021 ASH Annual Meeting & Exposition. This study, published in Blood, sought to determine the safety and efficacy of the COVID-19 vaccine for these patients. Specifically, with regard to safety, the study looked at the frequency of...